AU2010226613B2 - Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration - Google Patents

Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration Download PDF

Info

Publication number
AU2010226613B2
AU2010226613B2 AU2010226613A AU2010226613A AU2010226613B2 AU 2010226613 B2 AU2010226613 B2 AU 2010226613B2 AU 2010226613 A AU2010226613 A AU 2010226613A AU 2010226613 A AU2010226613 A AU 2010226613A AU 2010226613 B2 AU2010226613 B2 AU 2010226613B2
Authority
AU
Australia
Prior art keywords
pharmaceutical agent
antiarrhythmic
antiarrhythmic pharmaceutical
class
minutes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2010226613A
Other languages
English (en)
Other versions
AU2010226613A1 (en
Inventor
Rangachari Narasimhan
Carlos A. Schuler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incarda Therapeutics Inc
Original Assignee
Incarda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incarda Therapeutics Inc filed Critical Incarda Therapeutics Inc
Publication of AU2010226613A1 publication Critical patent/AU2010226613A1/en
Application granted granted Critical
Publication of AU2010226613B2 publication Critical patent/AU2010226613B2/en
Priority to AU2013248242A priority Critical patent/AU2013248242B2/en
Priority to AU2016256776A priority patent/AU2016256776B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2010226613A 2009-03-18 2010-03-18 Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration Active AU2010226613B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2013248242A AU2013248242B2 (en) 2009-03-18 2013-10-25 Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
AU2016256776A AU2016256776B2 (en) 2009-03-18 2016-11-10 Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21038209P 2009-03-18 2009-03-18
US61/210,382 2009-03-18
PCT/US2010/027740 WO2010107964A1 (en) 2009-03-18 2010-03-18 Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2013248242A Division AU2013248242B2 (en) 2009-03-18 2013-10-25 Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration

Publications (2)

Publication Number Publication Date
AU2010226613A1 AU2010226613A1 (en) 2011-09-29
AU2010226613B2 true AU2010226613B2 (en) 2013-07-25

Family

ID=42739985

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010226613A Active AU2010226613B2 (en) 2009-03-18 2010-03-18 Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration

Country Status (9)

Country Link
US (5) US8974828B2 (enExample)
EP (3) EP3552602B1 (enExample)
JP (5) JP2012520890A (enExample)
AU (1) AU2010226613B2 (enExample)
CA (2) CA2835771C (enExample)
DK (1) DK2413902T3 (enExample)
ES (3) ES2750359T3 (enExample)
PL (1) PL2413902T3 (enExample)
WO (1) WO2010107964A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2750359T3 (es) 2009-03-18 2020-03-25 Incarda Therapeutics Inc Dosis unitarias, aerosoles, kits y procedimientos para tratar afecciones cardíacas mediante administración pulmonar
EP2654864B1 (en) 2010-12-22 2020-10-28 Syqe Medical Ltd. System for drug delivery
US9713687B2 (en) 2012-08-21 2017-07-25 Philip Morris Usa Inc. Ventilator aerosol delivery system with transition adapter for introducing carrier gas
US11191755B2 (en) 2014-01-17 2021-12-07 Cornell University Compositions and methods for providing cardioprotective effects
TWI590837B (zh) * 2014-03-25 2017-07-11 林信湧 一種用於治療心臟病之吸入式醫藥組成物及其備製方法
CN106604755B (zh) 2014-06-30 2020-08-11 Syqe医药有限公司 流量调节的吸入器装置
EP3160565B1 (en) * 2014-06-30 2021-08-18 Syqe Medical Ltd. Devices and systems for pulmonary delivery of active agents
US11298477B2 (en) 2014-06-30 2022-04-12 Syqe Medical Ltd. Methods, devices and systems for pulmonary delivery of active agents
GB2542064B (en) * 2015-01-20 2020-11-18 Univ California Unit aerosol doses for anticoagulation
MD3283067T2 (ro) * 2015-04-14 2020-05-31 Milestone Pharmaceuticals Inc Săruri cu solubilitate mare în apă, cu acțiune scurtă a fenilalchilaminei ca blocant al canalului de calciu, și utilizarea acestora
ES2874087T3 (es) 2016-01-06 2021-11-04 Syqe Medical Ltd Tratamiento terapéutico con dosis bajas
CA3012333A1 (en) * 2016-02-01 2017-08-10 Incarda Therapeutics, Inc. Combining electronic monitoring with inhaled pharmacological therapy to manage cardiac arrhythmias including atrial fibrillation
WO2018209107A1 (en) * 2017-05-10 2018-11-15 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
ES3040411T3 (en) * 2018-03-22 2025-10-30 Incarda Therapeutics Inc A novel method to slow ventricular rate
US20210228825A1 (en) * 2018-06-05 2021-07-29 Incarda Therapeutics, Inc. Methods for diagnosing brugada syndrome using an aerosol
WO2019241597A1 (en) * 2018-06-14 2019-12-19 Cornell University Compositions and methods for providing cardioprotective effects
US12396970B2 (en) 2021-08-20 2025-08-26 AltaThera Pharmaceuticals LLC Anti-arrhythmic compositions and methods
US10512620B1 (en) 2018-08-14 2019-12-24 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US11696902B2 (en) 2018-08-14 2023-07-11 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US11344518B2 (en) * 2018-08-14 2022-05-31 AltaThera Pharmaceuticals LLC Method of converting atrial fibrillation to normal sinus rhythm and loading oral sotalol in a shortened time frame
US11610660B1 (en) 2021-08-20 2023-03-21 AltaThera Pharmaceuticals LLC Antiarrhythmic drug dosing methods, medical devices, and systems
US11007185B2 (en) * 2019-08-01 2021-05-18 Incarda Therapeutics, Inc. Antiarrhythmic formulation
KR102891439B1 (ko) * 2019-08-01 2025-11-25 인카다 테라퓨틱스, 인크. 항부정맥 제제
JP2024502236A (ja) * 2020-12-17 2024-01-18 インカーダ セラピューティクス， インコーポレイテッド 心房性不整脈を有する対象におけるカルディオバージョンの誘導のためのキットおよび方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080275036A1 (en) * 2007-05-02 2008-11-06 Apt Pharmaceuticals, Inc. Prevention and treatment of cardiac conditions

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
IT1016489B (it) 1974-03-18 1977-05-30 Isf Spa Inalatore
SE408265B (sv) 1975-12-12 1979-06-05 Draco Ab Anordning for koldioxiddriven endosaerosol, avsedd for inhalering
US4247066A (en) 1978-02-21 1981-01-27 General Dynamics Corporation Airfoil variable cambering device and method
IT1116047B (it) 1979-04-27 1986-02-10 Sigma Tau Ind Farmaceuti Dispositivo per la rapida inalazione di farmaci in polvere da parte di persone sofferenti di asma
DE3634952A1 (de) 1986-10-14 1988-04-21 Bayer Ag Imidazo-pyrrolo-pyridin-derivate
JP3202705B2 (ja) * 1987-11-06 2001-08-27 リサーチ ディベロップメント ファンデーション 医療用のリポソームおよび薬物含有リポソームのエアゾールの小粒子
US4962095A (en) * 1989-02-15 1990-10-09 E. R. Squibb & Sons, Inc. Method of reducing pre-and post-ischemic myocardial arrhythmias and fibrillation
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
EP0940154B1 (en) 1991-07-02 2007-04-18 Nektar Therapeutics Device for delivering aerosolized medicaments
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
KR100419037B1 (ko) 1994-03-07 2004-06-12 넥타르 테라퓨틱스 폐를통한인슐린의전달방법및그조성물
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
AU696387B2 (en) 1994-05-18 1998-09-10 Inhale Therapeutic Systems, Inc. Methods and compositions for the dry powder formulation of interferons
JP3388896B2 (ja) 1994-08-08 2003-03-24 株式会社日立ユニシアオートモティブ 吸入式投薬器
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
ATE287703T1 (de) 1995-04-14 2005-02-15 Nektar Therapeutics Pulverförmige pharmazeutische formulierungen mit verbesserter dispergierbarkeit
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US6503480B1 (en) 1997-05-23 2003-01-07 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5976574A (en) 1996-12-31 1999-11-02 Inhale Therapeutic Systems Processes for spray drying hydrophobic drugs in organic solvent suspensions
US20020017295A1 (en) 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
KR100575070B1 (ko) 1997-09-29 2006-05-03 넥타르 테라퓨틱스 안정화된 생활성 제제 및 이의 사용 방법
WO1999016420A1 (en) 1997-09-29 1999-04-08 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in nebulizers
US6541479B1 (en) * 1997-12-02 2003-04-01 Massachusetts College Of Pharmacy Calcium channel blockers
US6257233B1 (en) 1998-06-04 2001-07-10 Inhale Therapeutic Systems Dry powder dispersing apparatus and methods for their use
DE19835346A1 (de) 1998-08-05 2000-02-10 Boehringer Ingelheim Pharma Zweiteilige Kapsel zur Aufnahme von pharmazeutischen Zubereitungen für Pulverinhalatoren
IL143046A0 (en) 1998-11-12 2002-04-21 Pilkiewicz Frank G An inhalation system
ATE422924T1 (de) 1999-05-28 2009-03-15 Nektar Therapeutics Gerät zum abgeben von abgemessenen mengen von medikamente beinhaltendem aerosol
CA2406206C (en) * 2000-04-17 2012-03-20 Vectura Limited Improvements in or relating to formulations for use in inhaler devices
PT1280520E (pt) 2000-05-10 2014-12-16 Novartis Ag Pós à base de fosfolípidos para administração de fármacos
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US6357490B1 (en) 2000-08-22 2002-03-19 Advanced Inhalation Research, Inc. System, method and apparatus for filling containers
FI20002215A0 (fi) * 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
EP1343372A2 (en) 2000-12-21 2003-09-17 Nektar Therapeutics Pulmonary delivery of polyene antifungal agents
BR0208012A (pt) 2001-03-20 2004-03-02 Glaxo Group Ltd Usos de pelo menos duas drogas e um propelente hfa e de pelo menos uma composição farmaceêutica, e, inalador acondicionado para tratar asma
US6766799B2 (en) 2001-04-16 2004-07-27 Advanced Inhalation Research, Inc. Inhalation device
US7090830B2 (en) * 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
EP1392262A1 (en) * 2001-05-24 2004-03-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
US20070122353A1 (en) * 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US20080038363A1 (en) * 2001-05-24 2008-02-14 Zaffaroni Alejandro C Aerosol delivery system and uses thereof
JP4795637B2 (ja) * 2001-09-28 2011-10-19 カーブ テクノロジー，インコーポレイティド 鼻ネブライザー
CA2482928A1 (en) * 2002-04-18 2003-10-30 Cv Therapeutics, Inc. Method of treating arrhythmias comprising administration of an a1 adenosine agonist with a beta blocker, calcium channel blocker or a cardiac glycoside
US8245708B2 (en) 2002-05-07 2012-08-21 The Research Foundation Of State University Of New York Methods, devices and formulations for targeted endobronchial therapy
US7607436B2 (en) 2002-05-06 2009-10-27 The Research Foundation Of State University Of New York Methods, devices and formulations for targeted endobronchial therapy
EP1515768B1 (en) 2002-05-07 2013-11-06 The State University of New York at Stony Brook Devices for targeted endobronchial therapy
WO2004060351A2 (en) 2002-12-31 2004-07-22 Nektar Therapeutics Pharmaceutical formulation with an insoluble active agent for pulmonary administration
US20050009776A1 (en) * 2003-04-24 2005-01-13 Aderis Pharmaceuticals, Inc. Method of treating atrial fibrillation or atrial flutter
WO2005018635A2 (en) * 2003-08-07 2005-03-03 Cardiome Pharma Corp. Ion channel modulating activity i
EP1755623A4 (en) * 2004-05-21 2007-10-17 Transave Inc TREATMENT OF LUNG DISEASES AND BEFORE A PULMONARY DISEASE
US8569277B2 (en) 2004-08-11 2013-10-29 Palo Alto Investors Methods of treating a subject for a condition
TWI396541B (zh) 2005-10-10 2013-05-21 Boehringer Ingelheim Int 用於治療呼吸疾病之新穎藥物組合
ITMI20051999A1 (it) * 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
EP1951672B1 (en) * 2005-10-21 2011-05-25 Merck Sharp & Dohme Corp. Potassium channel inhibitors
CL2007002689A1 (es) 2006-09-18 2008-04-18 Vitae Pharmaceuticals Inc Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
ES2596263T3 (es) 2006-10-25 2017-01-05 Novartis Ag Aparato de dispersión de polvo
WO2008066745A1 (en) 2006-11-22 2008-06-05 Reliant Pharmaceuticals, Inc. Prophlyaxis and treatment of atrial fibrillation with omega-3 fatty acids
TW200840578A (en) 2006-12-15 2008-10-16 Procter & Gamble Compositions of azimilide dihydrochloride
WO2008134630A1 (en) * 2007-04-30 2008-11-06 Apt Pharmaceuticals Dexrazoxane compounds for cardioprotection
US20110144125A1 (en) 2008-08-14 2011-06-16 The Uab Research Foundation Anti-Arrhythmia Agents, Methods of Their Use, Methods of Their Identification and Kits Therefore
US8501727B2 (en) * 2008-08-22 2013-08-06 Milestone Pharmaceuticals Inc. Short acting benzothiazepine calcium channel blockers and uses thereof
JP5730316B2 (ja) * 2008-09-23 2015-06-10 ラボラトリー スキン ケア インコーポレイテッド 活性剤を充填した、均一、硬質、球状のナノ多孔質リン酸カルシウム粒子の製造方法
ES2750359T3 (es) 2009-03-18 2020-03-25 Incarda Therapeutics Inc Dosis unitarias, aerosoles, kits y procedimientos para tratar afecciones cardíacas mediante administración pulmonar

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080275036A1 (en) * 2007-05-02 2008-11-06 Apt Pharmaceuticals, Inc. Prevention and treatment of cardiac conditions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BORLAK J, et al. 'Metabolism of Verapamil in Cultures of Rat Alveolar Epithelial Cells and Pharmacokinetics After Administration By Intravenous and Inhalation Routes,' Drug Metabolism and Disposition, (2005), Vol 33 No 8, pp 1108-1114. *
RABINOWITZ JD, et al. 'Ultra-Fast Absorption of Amorphous Pure Drug Aerosols Via Deep Lung Inhalation,' Journal of Pharmaceutical Sciences, (2006) Vol 95 No 11, pp 2438-2451. *

Also Published As

Publication number Publication date
AU2010226613A1 (en) 2011-09-29
JP2012520890A (ja) 2012-09-10
US20190060230A1 (en) 2019-02-28
EP3552603B1 (en) 2024-11-06
US20120003318A1 (en) 2012-01-05
JP2015193657A (ja) 2015-11-05
EP3552602A1 (en) 2019-10-16
EP3552602B1 (en) 2025-03-05
CA2755809C (en) 2014-02-18
EP3552603A1 (en) 2019-10-16
ES2750359T3 (es) 2020-03-25
JP2019019139A (ja) 2019-02-07
CA2835771A1 (en) 2010-09-23
ES3003038T3 (en) 2025-03-10
US8974828B2 (en) 2015-03-10
CA2755809A1 (en) 2010-09-23
EP3552603C0 (en) 2024-11-06
JP7071949B2 (ja) 2022-05-19
CA2835771C (en) 2017-01-24
EP3552602C0 (en) 2025-03-05
US20150313842A1 (en) 2015-11-05
ES3036464T3 (en) 2025-09-19
EP2413902A1 (en) 2012-02-08
US10045939B2 (en) 2018-08-14
US20180318213A1 (en) 2018-11-08
JP6715305B2 (ja) 2020-07-01
JP2017160268A (ja) 2017-09-14
EP2413902A4 (en) 2014-02-19
WO2010107964A1 (en) 2010-09-23
EP2413902B1 (en) 2019-07-17
DK2413902T3 (da) 2019-10-07
PL2413902T3 (pl) 2020-01-31
US20180296480A1 (en) 2018-10-18
JP2019203032A (ja) 2019-11-28

Similar Documents

Publication Publication Date Title
AU2010226613B2 (en) Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
AU2013248242B2 (en) Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
AU2018266199A1 (en) Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
CA3200432A1 (en) Kits and methods for induction of cardioversion in subjects with atrial arrhythmias
US10744087B2 (en) Method to slow ventricular rate
AU2016256776B2 (en) Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
HK40013848B (en) Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
HK40013848A (en) Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
HK40013847A (en) Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
HK1166952A (en) Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
HK1166952B (en) Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
HK40013847B (en) Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)